[1]陈伟国,王想福,叶丙霖,等.二仙汤联合经皮球囊扩张椎体后凸成形术治疗绝经后骨质疏松性椎体压缩性骨折临床研究[J].中国中医药信息杂志,2019,26(6):14-18.[doi:10.3969/j.issn.1005-5304.2019.06.004]
 CHEN Weiguo,WANG Xiangfu,YE Binglin,et al.Clinical Study on Erxian Decoction Combined with PKP in Treatment of Osteoporotic Vertebral Compression Fractures with Postmenopausal Osteoporosis[J].zhongguo zhongyiyao xinxi zazhi,2019,26(6):14-18.[doi:10.3969/j.issn.1005-5304.2019.06.004]
点击复制

二仙汤联合经皮球囊扩张椎体后凸成形术治疗绝经后骨质疏松性椎体压缩性骨折临床研究

参考文献/References:

[1] 李毅中,蔡思清,颜丽笙,等.DXA影像评估绝经后女性椎体骨折[J]. 中国骨质疏松杂志,2014,11(20):1330-1334.
[2] 胡侦明,杨惠林,王根林,等.经皮椎体成形术治疗的相关建议[J].中华骨与关节外科杂志,2015,8(5):375-376.
[3] 宋建东,陈子健,李停,等.单、双侧经椎弓根途径PKP术治疗骨质疏松性胸椎压缩性骨折的临床疗效对比[J].中国中医骨伤科杂志,2017, 25(11):33-35.
[4] 葛继荣,郑洪新,万小明,等.中医药防治原发性骨质疏松症专家共识(2015)[J].中国骨质疏松杂志,2015,21(9):1023-1028.
[5] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中国全科医学,2017,20(32):3963-3982.
[6] 张智海,刘忠厚,李娜,等.中国人骨质疏松症诊断标准专家共识(第三稿?2014版)[J].中国骨质疏松杂志,2014,20(9):1007-1010.
[7] COMPSTON J. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843[M]. Geneva:WHO,1994:584.
[8] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:355-360.
[9] JENSEN M P, KAROLY P, BRAVER S. The measurement of clinical painintensity:a comparison of six methods[J]. Pain,1986,27(1):117-126.
[10] SI L, WINZENBERG T M, JIANG Q, et al. Projection of osteoporosis-related fractures and costs in China:2010-2050[J]. Osteoporos Int,2015,26(7):1929-1937.
[11] WANG G, YANG H, CHEN K. Osteoporotic vertebral compression fractures with an intravertebral cleft treated by percutaneous balloon kyphoplasty[J]. J Bone Joint Surg Br,2010,92(11):1553-1557.
[12] GALIBERT P, DERANMND H, ROSAT P, et a1. Preliminary note on thetreatment of vertebral ansiom by pereutanoous acrylic vertebroplasty[J]. Neurechirurgie,1987,33:166-168.
[13] 蒋安清,姜为民,王根林,等.骨质疏松性椎体压缩骨折PKP术后再发椎体骨折的原因及相关危险因素分析[J].中国脊柱脊髓杂志,2016, 26(10):951-953.
[14] KLAZEN C A, VENMANS A, DE V J, et al. Percutaneous vertebro plasty is not a risk factor for new osteoporotic compression fractures:results from VERTOSⅡ[J]. Am J Neuroradiol,2010, 31(8):1447-1450.
[15] 朱书涛,刘洋,张明辉,等.PKP术后患者再骨折危险因素分析[J].中国矫形外科杂志,2016,24(16):1445-1448.
[16] 乐进,尹佩玉,韩庭良,等.强筋壮骨丸辅助经皮椎体后凸成形术治疗骨质疏松性椎体压缩骨折临床研究[J].中国中医药信息杂志,2018, 25(5):32-35.
[17] 朱宝,宋瑞平,赵继荣,等.基于“乙癸同源”理论探讨绝经后骨质疏松症的中医药治疗[J].中国骨质疏松杂志,2017,23(1):116-121.
[18] 郭强,赵欢,雷星星,等.辨证论治治疗绝经后骨质疏松症临床观察[J].时珍国医国药,2016,27(8):1920-1922.
[19] 叶丙霖,李盛华,李淑玲,等.二仙汤联合依降钙素治疗绝经期妇女骨质疏松症临床研究[J].中国中医药信息杂志,2016,23(6):23-26.
[20] 刘波,陈明,李姗姗,等.二仙汤对去卵巢大鼠骨质疏松的影响[J].中国骨质疏松杂志,2014,20(2):129-132.(收稿日期:2018-08-05)(修回日期:2018-10-05;编辑:季巍巍)

相似文献/References:

[1]赵仁霞.二仙汤加味治疗卵巢早衰临床观察[J].中国中医药信息杂志,2010,17(1):62.
 [J].zhongguo zhongyiyao xinxi zazhi,2010,17(6):62.
[2]杨明,丁春燕,张娴,等.二仙汤疗效与细胞色素P450 1A2酶基因多态性关系的研究[J].中国中医药信息杂志,2008,15(7):12.
 YANG Ming,DING Chun-Yan,ZHANG Xian,et al.Genetic Association Research between Mutation in CYP1A2 Gene and Erxian Soup Response[J].zhongguo zhongyiyao xinxi zazhi,2008,15(6):12.
[3]凌文浩,指导:杨明.二仙汤在男科疾病中的研究进展[J].中国中医药信息杂志,2011,18(10):102.[doi:10.3969/j.issn.1005-5304.2011.10.051]
 [J].zhongguo zhongyiyao xinxi zazhi,2011,18(6):102.[doi:10.3969/j.issn.1005-5304.2011.10.051]
[4]杨明,任东林,卢运田,等.二仙汤治疗肾虚证男性更年期综合征疗效观察[J].中国中医药信息杂志,2006,13(11):82.
 [J].zhongguo zhongyiyao xinxi zazhi,2006,13(6):82.
[5]陶仕英,牛建昭,王继峰,等.二仙汤及其组方中药对幼年大鼠肾上腺雌激素受体表达的影响[J].中国中医药信息杂志,2010,17(5):38.
 TAO Shi-ying,NIU Jian-zhao,WANG Ji-feng,et al.Effects of Er-xian Decoction and Its Component Herbs on Estrogen Receptors in Adrenal Development Rats[J].zhongguo zhongyiyao xinxi zazhi,2010,17(6):38.
[6]李荣群,庄爱文,王 猛.二仙汤的研究现状与思考[J].中国中医药信息杂志,2004,11(6):553.
[7]叶丙霖,李盛华,李淑玲,等.二仙汤联合依降钙素治疗绝经期妇女骨质疏松症临床研究[J].中国中医药信息杂志,2016,23(6):23.[doi:10.3969/j.issn.1005-5304.2016.06.007]
 YE Bing-lin,LI Sheng-hua,LI Shu-ling,et al.Clinical Study on Erxian Decoction Combined with Elcatonin in the Treatment of Postmenopausal Osteoporosis[J].zhongguo zhongyiyao xinxi zazhi,2016,23(6):23.[doi:10.3969/j.issn.1005-5304.2016.06.007]

备注/Memo

基金项目:甘肃省中医药管理局科研课题(GZK-2016-59)
通讯作者:王想福,E-mail:wangxf_1969@163.com

更新日期/Last Update:

2019-05-21